title: Chromatin proteins as a possible target for antitumour agents: alterations of chromatin proteins in dibromodulcitol treated Yoshida tumors.
abstract: The effect of dibromodulcitol (DBD) on Yoshida sarcoma chromatin components has been investigated. Measurements on the radioactivity of nuclear components after in vivo treatment with [3H]DBD for 1 h indicated preferential drug binding to the high molecular weight component of the nuclear residual acidic protein (non-histones) and also to Histone 1 (H1) (very lysine rich, F1). Two-hour DBD treatment resulted in partial degradation and reduced [3H]leucine incorporation into the same fractions of chromatin. However, 6 h after DBD treatment, the synthesis of the degraded chromatin proteins began and by 24 h was completed. During the same treatment period the composition of chromatin showed a remarkable alteration; 2 h after DBD treatment the amount of the nuclear residual acidic proteins relative to DNA decreased by approx. 50%, but returned to control value 24 h after drug treatment. This in conjunction with the data on [3H]leucine incorporation suggests that certain chromatin proteins are degraded and subsequently newly synthesised after DND treatment resulting in an exchange of chromatin components. The formation of a nucleohistone complex between H1 and DNA was inhibited by pretreatment of H1 and DBD, dianhydrodulcitol (DAD) and bischloroethylnitrosourea (BCNU).
mesh_terms: D000818:Animals; D002843:Chromatin / Q000187:drug effects*; D002868:Chromosomal Proteins, Non-Histone / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D006657:Histones / Q000378:metabolism; D008936:Mitolactol / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000096:biosynthesis; D051381:Rats; D012517:Sarcoma, Yoshida / Q000378:metabolism*
chemical_list: D002843:Chromatin; D002868:Chromosomal Proteins, Non-Histone; D004273:DNA, Neoplasm; D006657:Histones; D009363:Neoplasm Proteins; D008936:Mitolactol